[11] Saxenda (liraglutide) [prescribing information]
Each option has different administration schedules and practical considerations, and experiences can vary
Commonly affected areas include the arms, neck, submental region, abdomen, thighs, and face, where rapid fat loss leads to visible sagging
Glp-1a: going beyond traditional use
The Precision Peptide Genetic Test evaluates key variants in GIPR (rs1800437), and metabolic markers like FTO and MC4R that may help provide context for how your body distributes and metabolizes fat tissue, potentially informing injection site considerations
Report any severe or unexpected side effects immediately